AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

AbbVie, Inc. adalah perusahaan biopharmaceutical berbasis riset yang terlibat dalam pengembangan dan penjualan produk farmasi. Perusahaan ini berkantor pusat di North Chicago, Illinois dan saat ini mempekerjakan 57.000 karyawan penuh waktu. Perusahaan melaksanakan penawaran umum perdana (IPO) pada 2 Januari 2013. Perusahaan terlibat dalam penelitian dan pengembangan, produksi, komersialisasi, dan penjualan obat-obatan dan terapi. Portofolio produknya mencakup Imunologi, Onkologi, Estetika, Ilmu Saraf, Perawatan Mata, dan Produk Utama Lainnya. Produk Imunologi mencakup reumatologi, dermatologi, dan gastroenterologi. Produk Onkologi mencakup Imbruvica, Venclexta/Venclyxto, Elahere, dan Epkinly. Portofolio Estetika terdiri dari injeksi wajah, plastik dan kedokteran regeneratif, kontur tubuh, dan produk perawatan kulit. Produk Ilmu Sarafnya mencakup Botox Terapeutik, Vraylar, Duopa dan Duodopa, Ubrelvy, dan Qulipta. Produk Perawatan Mata mencakup Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, dan produk perawatan mata lainnya. Produk utama lainnya termasuk Mavyret/Maviret, Creon, dan Linzess/Constella. Kandidat investigasi mereka, bretisilocin, ditujukan untuk pengobatan pasien dengan gangguan depresi mayor (MDD) sedang hingga berat.

AbbVie Stock

About AbbVie

Key Statistics

Insights